JUMPCAN(SH:600566) Guang Zhou Ri Bao·2026-02-27 10:04Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for the exclusive commercialization rights of Zeli Mei® in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan, including 125 million yuan upfront and 65 million yuan in milestone payments [2] - Zeli Mei® is a non-hormonal innovative drug developed by Zedman, recognized as the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [3] - The collaboration is seen as a significant milestone for Zedman in market expansion and resource complementarity, aiming to enhance pediatric and dermatological treatments in China [2][3] Group 2 - Zedman’s CEO emphasized the importance of this partnership in maximizing the innovative value of Zeli Mei® and accelerating its internationalization process [3] - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product portfolio in pediatric and dermatological treatments, showcasing the strength of Chinese innovation in the dermatology field [3]